BSE Live
Oct 17, 16:01Prev. Close
2474.20
Open Price
2447.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 17, 15:58Prev. Close
2458.20
Open Price
2447.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2438.50 (4)
Profit & Loss account of Ajanta Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 4,261.45 | 3,924.00 | 3,376.15 | 3,083.78 | 2,674.10 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 4,261.45 | 3,924.00 | 3,376.15 | 3,083.78 | 2,674.10 | |
Total Operating Revenues | 4,322.04 | 3,971.12 | 3,411.27 | 3,140.64 | 2,718.59 | |
Other Income | 119.87 | 116.48 | 132.75 | 139.73 | 103.57 | |
Total Revenue | 4,441.91 | 4,087.60 | 3,544.02 | 3,280.37 | 2,822.16 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 846.60 | 939.43 | 878.36 | 773.04 | 704.09 | |
Purchase Of Stock-In Trade | 184.00 | 162.16 | 149.04 | 116.12 | 100.59 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -18.58 | -22.17 | -21.99 | -56.60 | -74.60 | |
Employee Benefit Expenses | 1,010.90 | 834.16 | 720.41 | 585.87 | 498.11 | |
Finance Costs | 4.60 | 6.80 | 5.23 | 9.12 | 6.90 | |
Depreciation And Amortisation Expenses | 139.93 | 132.16 | 126.95 | 120.96 | 111.49 | |
Other Expenses | 1,094.40 | 938.11 | 986.17 | 831.32 | 573.49 | |
Total Expenses | 3,261.85 | 2,990.65 | 2,844.17 | 2,379.83 | 1,920.07 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,180.06 | 1,096.95 | 699.85 | 900.54 | 902.09 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 1,180.06 | 1,096.95 | 699.85 | 900.54 | 902.09 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 283.01 | 253.74 | 122.40 | 196.72 | 225.06 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | 5.14 | 12.13 | -2.93 | 9.51 | 9.77 | |
Tax For Earlier Years | -24.98 | 23.84 | 21.66 | -25.55 | -8.38 | |
Total Tax Expenses | 263.17 | 289.71 | 141.13 | 180.68 | 226.45 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 916.89 | 807.24 | 558.72 | 719.86 | 675.64 | |
Profit/Loss From Continuing Operations | 916.89 | 807.24 | 558.72 | 719.86 | 675.64 | |
Profit/Loss For The Period | 916.89 | 807.24 | 558.72 | 719.86 | 675.64 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 73.28 | 64.11 | 43.61 | 83.28 | 77.59 | |
Diluted EPS (Rs.) | 73.25 | 64.06 | 43.61 | 83.28 | 77.59 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 349.75 | 642.17 | 89.69 | 82.21 | 82.90 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 31.64 | |
Equity Dividend Rate (%) | 1,400.00 | 2,550.00 | 350.00 | 475.00 | 475.00 |
22.09.2025
01.08.2025
29.07.2025
Ajanta Pharma Consolidated June 2025 Net Sales at Rs 1,302.65 crore, up 13.78% Y-o-Y
29.07.2025
Ajanta Pharma Standalone June 2025 Net Sales at Rs 1,208.56 crore, up 12.19% Y-o-Y
29.07.2025
Ajanta Pharma Consolidated June 2025 Net Sales at Rs 1,302.65 crore, up 13.78% Y-o-Y
29.07.2025
Ajanta Pharma Standalone June 2025 Net Sales at Rs 1,208.56 crore, up 12.19% Y-o-Y
02.05.2025
Ajanta Pharma Consolidated March 2025 Net Sales at Rs 1,170.41 crore, up 11.04% Y-o-Y
02.05.2025
Ajanta Pharma Standalone March 2025 Net Sales at Rs 1,013.94 crore, up 9.49% Y-o-Y
12.07.2023
Ajanta Pharma Q1 PAT seen up 9.1% YoY to Rs 190.5 cr: Nirmal Bang
13.07.2022
Ajanta Pharma Q1 PAT may dip 12.7% YoY to Rs 151.6 cr: ICICI Direct
11.01.2019
Ajanta Pharma Q3 PAT may dip 35.1% YoY to Rs. 95.8 cr: ICICI Direct
12.10.2018
Ajanta Pharma Q2 PAT may dip 16.5% YoY to Rs. 110.1 cr: ICICI Direct